Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 15/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.49 |
| ▸ | FAP | Q12884 | 12/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.49 |
| ▸ | PREP | P48147 | 6/20 | 0.49 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25054844 | 1.00 | DPP4 (0.49) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL5027448 | 0.70 | — | — | |
| SCHEMBL24316273 | 0.70 | L3MBTL1 (0.32) | — | |
| SCHEMBL24109224 | 0.70 | — | — | |
| SCHEMBL7941599 | 0.70 | — | — | |
| SCHEMBL15024851 | 0.68 | DPP4 (0.57) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL9963376 | 0.67 | — | — | |
| SCHEMBL681681 | 0.67 | — | — | |
| SCHEMBL25124990 | 0.67 | — | — | |
| SCHEMBL26999718 | 0.67 | CHRNB4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144379-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20100184706-A1 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE | 2010-07-22 | — | — | US | disclosed |
| US-20100105753-A1 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105753-A1 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof | FAP, FIBP, DNPEP | DPP4 166/4885DPP7 44/4885DPP8 96/4885 |
| US-20100184706-A1 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | FAP, DPYD, TYMP | DPP4 219/4885DPP7 245/4885DPP8 321/4885 |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | DPP4 3936/4885DPP7 3132/4885DPP8 3154/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | DPP4 3936/4885DPP7 3132/4885DPP8 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.